Outcome of Immunosuppressive Therapy with Helicobacter pylori Eradication Therapy in Patients with Chronic Idiopathic Thrombocytopenic Purpura
article
OA: gold
CC0
Abstract
We initiated this study to investigate whether combining Helicobacter pylori eradication with immunosuppressive therapy provides an additional benefit to patients with idiopathic thrombocytopenic purpura (ITP) that has relapsed or has not responded to steroid and/or danazol therapy in patients who have H. pylori infection. Thirty- four patients with chronic ITP that had relapsed or failed to steroid and/or danazol therapy were assessed for H. pylori infection. Of the 21 confirmed cases, 12 patients were given H. pylori eradication therapy alone (EA), while 9 patients received eradication therapy combined with immunosuppressive therapy (EI). The response rate was not significantly different between patients in the EA and those in the EI group (41.7% in the EA group vs. 66.7% in the EI group, p=0.345). The median platelet count at 6 months after therapy was higher in the EI group patients (75 x 10(9)/L in the EI group patients vs. 18 x 10(9)/L in the EA group patients, p=0.028). The median response duration was also longer in the EI group patients (9 months in the EI group patients vs. 3 months in the EA group patients, p=0.049). These results show that a significant benefit is gained by the use of H. pylori eradication combined with immunosuppressive therapy over the use of eradication therapy alone for patients with chronic ITP.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (27)
- doi:10.1046/j.1523-5378.2001.00028.x via openalex
- doi:10.1007/s00277-002-0579-8 via openalex
- doi:10.1056/nejm199405053301803 via openalex
- doi:10.1002/(sici)1097-0215(19970729)72:3<453::aid-ijc13>3.0.co;2-d via openalex
- doi:10.1002/mpo.2950100110 via openalex
- doi:10.1046/j.1365-2141.2001.03194.x via openalex
- doi:10.1016/s0140-6736(05)60004-9 via openalex
- doi:10.1046/j.1365-2141.2002.363010.x via openalex
- W207413417 via openalex
- doi:10.1007/bf02983220 via openalex
- doi:10.1016/s0016-5085(99)70161-7 via openalex
- doi:10.1182/blood.v97.3.812 via openalex
- doi:10.1056/nejm199304293281703 via openalex
- W2274629221 via openalex
- doi:10.1046/j.1365-2141.2002.03612.x via openalex
- doi:10.1046/j.1365-2257.1998.00148.x via openalex
- doi:10.1016/s0016-5085(97)70019-2 via openalex
- doi:10.1056/nejm198105073041904 via openalex
- doi:10.1046/j.1365-2141.2003.04735.x via openalex
- doi:10.1016/0002-9343(87)90490-6 via openalex
- doi:10.1182/blood-2002-05-1348 via openalex
- doi:10.1097/00004836-199806000-00008 via openalex
- doi:10.1182/blood.v56.3.329.bloodjournal563329 via openalex
- doi:10.1016/s0753-3322(99)80092-4 via openalex
- doi:10.1182/blood-2003-03-0900 via openalex
- doi:10.1182/blood.v56.3.329.329 via openalex
- doi:10.1046/j.1440-1746.1999.01974.x via openalex
Source provenance
- openalex
- last seen: 2026-05-10T10:51:31.144439+00:00
License: CC0
· commercial use OK